现实世界中广泛期小细胞肺癌癌症经免疫治疗后胸部放射治疗的有效性和安全性。

IF 4.2 3区医学 Q2 ONCOLOGY

Clinical & Experimental Metastasis Pub Date : 2023-10-01 Epub Date: 2023-08-16 DOI:10.1007/s10585-023-10227-5

Min Fang, Le Wang, Qing Gu, Huiwen Wu, Xianghui Du, Xiaojing Lai

{"title":"现实世界中广泛期小细胞肺癌癌症经免疫治疗后胸部放射治疗的有效性和安全性。","authors":"Min Fang, Le Wang, Qing Gu, Huiwen Wu, Xianghui Du, Xiaojing Lai","doi":"10.1007/s10585-023-10227-5","DOIUrl":null,"url":null,"abstract":"The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world.\",\"authors\":\"Min Fang, Le Wang, Qing Gu, Huiwen Wu, Xianghui Du, Xiaojing Lai\",\"doi\":\"10.1007/s10585-023-10227-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis.\",\"PeriodicalId\":10267,\"journal\":{\"name\":\"Clinical & Experimental Metastasis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Experimental Metastasis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10585-023-10227-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/8/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Experimental Metastasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10585-023-10227-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

免疫疗法联合化疗已成为晚期癌症（ES-SCLC）的标准治疗策略。CREST试验报告，合并胸部放疗（cTRT）提高了化疗后伴有胸内残留的ES-SCLC的总生存率（OS）。在这项研究中，接受免疫治疗的ES-SCLC患者被分配接受TRT或不接受TRT。TRT显著改善了无进展生存期（PFS）、局部无复发生存期（LRFS）和OS，并具有良好的耐受性毒性。进一步的亚队列分析显示，TRT显著改善了寡转移和无肝转移患者的LRFS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world.

查看原文本刊更多论文

Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world.

The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical & Experimental Metastasis 医学-肿瘤学

CiteScore

7.80

自引率

5.00%

发文量

审稿时长

12 months

期刊介绍： The Journal''s scope encompasses all aspects of metastasis research, whether laboratory-based, experimental or clinical and therapeutic. It covers such areas as molecular biology, pharmacology, tumor biology, and clinical cancer treatment (with all its subdivisions of surgery, chemotherapy and radio-therapy as well as pathology and epidemiology) insofar as these disciplines are concerned with the Journal''s core subject of metastasis formation, prevention and treatment.